Chonluten

Mechanism of action

Proposed by its developers to change gene expression in bronchial and alveolar cells. The one indexed study that names Chonluten is in a human monocyte cell line, where it lowered TNF and IL-6 release after a bacterial endotoxin challenge (Avolio et al., 2022); no animal study of airway inflammation was found.

Primary uses

• Investigational support in chronic respiratory disease (Russian literature)
• Research into respiratory aging

Typical dosing

Educational information, not medical advice. The doses on this page come from approved labels, published studies and, where no study exists, amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.

Regulatory status

Not FDA-approved. Marketed in Russia as a bioregulator supplement.

Status as of this entry's last review, October 4, 2026. Approvals, compounding rules and sport rules change; the regulatory tracker is checked more often.

What we checked

One paper indexed on PubMed names Chonluten, in its abstract rather than its title. This section records what can be checked: the identity, the regulatory status on the date below, that study, and every search we ran.

Identity, computed

The Methods section of Avolio et al. (2022) states that the Chonluten used was the tripeptide Glu-Asp-Gly, synthesised from a natural lung-derived counterpart. The dataset's formula and mass agree with the calculator for that sequence.

Regulatory status, read October 4, 2026

Drugs@FDA: 0 records for “chonluten”. EMA medicines list: 0 records for “chonluten”. Run for semaglutide, the same queries return 6 and 5 records (and the registry search 84 trials), so a zero here is an absence, not a broken search. Not named on the WADA 2026 and 2027 Prohibited Lists. As a substance with no current approval for human therapeutic use, it falls under section S0 (non-approved substances), which is prohibited at all times; the lists were read on September 27, 2026.

What the maker or sellers claim

Claim, from Avolio et al. (2022), describing Khavinson's work: Chonluten is a synthetic bronchial bioregulator whose main targets are in the respiratory system. Their own experiment was in blood-derived immune cells, not airway tissue.

About the family, not this compound

The Khavinson peptides are di-, tri- and tetrapeptides developed at the Saint Petersburg Institute of Bioregulation and Gerontology, most first isolated from animal tissue extracts and later made synthetically. The group proposes that they reach the cell nucleus and change gene expression in the tissue they are named for. Nearly all of the indexed work comes from that group and its collaborators.

A 2023 modelling study from the same group docked 26 of these short peptides, including AED, EDL, EDG and KEDG, into the amino-acid and peptide transporters LAT1, LAT2 and PEPT1, and proposed those transporters as their route into cells (Khavinson et al., 2023). It is a computer model of binding, not a measurement in cells, and it says nothing about any one product's effects.

What the one study shows

Avolio and colleagues, working in Italy, compared five Khavinson preparations in THP-1 cells, a human monocyte line. Chonluten increased tyrosine phosphorylation of growth-signalling kinases, and when the cells were challenged with bacterial lipopolysaccharide it reduced their TNF and IL-6 output, which the authors linked to TNF tolerance (Avolio et al., 2022). That is an anti-inflammatory signal in a cell line, not a result in lungs or patients. The 2023 transporter model above ranked EDG among the strongest binders and speculated that this could relate to anti-tumour effects; that remains a hypothesis.

What we looked for and did not find

No animal study of airway inflammation, no study in bronchial or lung tissue, no human trial, no pharmacokinetic data, no registry record and no dose from a controlled study. The sequence search returns more than 170 records, nearly all fragments of larger proteins or epitalon (Ala-Glu-Asp-Gly) papers that contain the letters.

References

1. [pubmed] Khavinson VKh, et al. "[Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results]." Adv Gerontol, 2013;26(1):20-37. PMID: 24003726.
2. [pubmed] Avolio F, et al. "Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line." Int J Mol Sci, 2022;23(7). PMID: 35408963.
3. [pubmed] Khavinson VK, et al. "Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters." Biomolecules, 2023;13(3). PMID: 36979488.

Related peptides

Guides & tools